Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 6/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26637806 | 0.81 | LSS (0.36) | LSSKMT2ACNR2 | |
| SCHEMBL15164669 | 0.78 | LSS (0.35) | LSSKMT2ACNR2 | |
| SCHEMBL310618 | 0.78 | LSS (0.35) | LSSKMT2ACNR2MEN1CYP3A4 | |
| SCHEMBL14518213 | 0.78 | LSS (0.35) | LSSKMT2ACNR2 | |
| SCHEMBL9650230 | 0.78 | LSS (0.35) | LSSKMT2ACNR2MEN1CYP3A4 | |
| SCHEMBL11001883 | 0.78 | LSS (0.35) | LSSKMT2ACNR2MEN1CYP3A4 | |
| SCHEMBL10629087 | 0.78 | LSS (0.35) | LSSKMT2ACNR2MEN1CYP3A4 | |
| SCHEMBL13815019 | 0.76 | ALOX15 (0.34) | LSSCNR2KDM4EALOX15 | |
| SCHEMBL10629003 | 0.76 | CD81 (0.33) | LSSCNR2ALOX15 | |
| SCHEMBL17967776 | 0.76 | CD81 (0.33) | LSSCNR2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212239-B2 | Method of making functionalized elastomer | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2015-12-15 | — | — | US | disclosed |
| US-8962759-B2 | Functionalized elastomer | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140357803-A1 | FUNCTIONALIZED ELASTOMER | GOODYEAR TIRE & RUBBER COMPANY, THE | 2014-12-04 | — | — | US | disclosed |
| US-20140357794-A1 | METHOD OF MAKING FUNCTIONALIZED ELASTOMER | GOODYEAR TIRE & RUBBER COMPANY, THE | 2014-12-04 | — | — | US | disclosed |
| US-20130274212-A1 | Sesterterpene Compounds and Use Thereof | SNU R&DB FOUNDATION (KR) | 2013-10-17 | — | — | US | disclosed |
| US-20130274212-A1 | Sesterterpene Compounds and Use Thereof | SNU R&DB FOUNDATION (KR) | 2013-10-17 | — | — | US | disclosed |
| US-8389164-B2 | Nonaqueous electrolytic solution, positive electrode and nonaqueous electrolyte secondary battery | SONY CORPORATION (JP) | 2013-03-05 | — | — | US | disclosed |
| US-8389164-B2 | Nonaqueous electrolytic solution, positive electrode and nonaqueous electrolyte secondary battery | SONY CORPORATION (JP) | 2013-03-05 | — | — | US | disclosed |
| US-8389164-B2 | Nonaqueous electrolytic solution, positive electrode and nonaqueous electrolyte secondary battery | SONY CORPORATION (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20100304224-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION, POSITIVE ELECTRODE AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | SONY CORPORATION (JP) | 2010-12-02 | — | — | US | disclosed |
| US-20100304224-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION, POSITIVE ELECTRODE AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | SONY CORPORATION (JP) | 2010-12-02 | — | — | US | disclosed |
| US-20100304224-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION, POSITIVE ELECTRODE AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | SONY CORPORATION (JP) | 2010-12-02 | — | — | US | disclosed |
| CN-101901933-A | Nonaqueous electrolytic solution, positive pole and rechargeable nonaqueous electrolytic battery | SONY CORP | 2010-12-01 | — | — | CN | disclosed |
| US-7550604-B2 | Pyrroloterpenes and use of the same as antimicrobial and anticancer agents | NEREUS PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274212-A1 | Sesterterpene Compounds and Use Thereof | LIPC, LIPE, FABP4 | LSS 34/4885KMT2A 4498/4885CNR2 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.